Therapeutic regimens for cancer generally involve drugs used in combinations. Most prior work has focused on identifying and understanding synergistic drug-drug interactions; however, understanding sources of antagonistic interactions remains an important and understudied issue. To enrich for antagonistic interactions and reveal common features of these drug combinations, we screened all pairwise combinations of drugs characterized as canonical activators of different forms of regulated cell death. We find that this network is strongly enriched for antagonistic interactions, and in particular, enriched for an extreme form of antagonism, which we call "single agent dominance". Single agent dominance refers to antagonisms in which a two drug combination phenocopies one of the two agents. We find that dominance results from differences in the cell death onset time, with dominant drugs inducing death earlier and at faster rates than their suppressed counterparts. Finally, we explored the mechanisms by which parthanatotic agents dominate apoptotic agents, finding that dominance in this scenario is caused by mutually exclusive and conflicting use of PARP1. Taken together, our study reveals death activation kinetics as a predictive feature of antagonism, due to inhibitory crosstalk between cell death pathways.
INTRODUCTION
Cancer therapies are often limited by issues such as acquired drug resistance and partial killing of a population of tumor cells 1, 2 . To combat these limitations, many efforts focus on the development of combination drug therapies [3] [4] [5] . Generally, most prior studies have focused on identifying combinations that produce synergistic drug-drug interactions. In contrast to expectations, however, recent reports have demonstrated that synergy is not generally observed in clinically efficacious drug combinations, which instead are typically additive 6 .
Synergistic drug combinations tend to reinforce the killing that would be induced by one of the single agents within the combination, rather than facilitating the killing of new cells that would not be killed by either of the single agents alone 7, 8 . Furthermore, synergistic combinations may also favor the future evolution of resistant clones 9 . While these data may limit the value of identifying drug synergies, understanding the sources of drug-drug antagonism still remains an important issue. It stands to reason that antagonism -particularly very strong antagonismmay limit the efficacy of a drug combination. Predicting which drug combinations will result in antagonism is challenging due to the lack of transparent "rules" underlying this phenomenon, as well as the unpredictable and often genotype specific nature of drug-drug interactions 10 . Thus, an unmet need is the identification of robust guiding principles that can be used to more efficiently identify, predict, or even improve upon antagonistic drug-drug interactions.
In the absence of robust principles to enable prediction of non-additive drug interactions, a common approach is to screen drug combinations, prioritizing the testing of drugs that target proteins with complementary functions. Several recent studies have successfully used known or predicted network topologies to enrich for non-additive drug combinations [11] [12] [13] [14] . Furthermore, network simulations have revealed topological features, such as negative feedback and mutual inhibition that may underlie the antagonism of drug combinations 15 . We envisioned that principles of drug-drug antagonism may emerge from studying drugs that target a network that was enriched for antagonistic interactions.
In recent years it has become clear that at least twelve mechanistically distinct forms of regulated cell death exist in mammalian cells 16 . Because these death pathways function in a mutually exclusive manner, we reasoned that drug combinations designed to co-activate multiple types of cell death may be enriched for antagonistic drug-drug interactions. Several lines of evidence already exist to suggest a degree of negative interaction and/or interdependent and mutually exclusive function among the various forms of cell death 17, 18 . For instance, activation of necroptosis requires inhibition of extrinsic apoptosis, due to cleavage of the pro-necroptotic protein RIPK1 by caspase-8 19 . Similarly, PARP1, the initiator of parthanatos, is cleaved by caspase-3, suggesting that activation of apoptosis also inhibits the cell's ability to activate parthanatos 20 . Although most potential interactions between death pathways have not explored, a model is beginning to emerge from these studies that mutually exclusive activation of cell death pathways may be enforced through inhibitory crosstalk between death regulatory pathways 16 .
To identify a robust set of antagonistic drug-drug interactions, we tested all pairwise combinations of the canonical activators for different cell death subtypes. We find that drug combinations comprised of cell death targeting drugs are enriched for drug antagonism, and in particular, strongly enriched for an extreme form of antagonism that we call "single agent dominance" (SAD). In SAD combinations, the two drug combination phenocopies one of the two single drugs. Importantly, this occurs even when the dominant drug is the less efficacious of the two compounds. Using multivariate statistical modeling we find that a key feature of SAD combinations is a large discrepancy in the timing of cell death onset, with faster acting drugs suppressing slower acting drugs, leading to strong antagonism. These antagonistic phenotypes could be relieved by temporally phasing drug addition to promote synchronized co-activation of multiple death pathways. Finally, we explore the molecular mechanisms of SAD combinations involving apoptotic and parthanatotic agents, finding that mutually exclusive but conflicting use of PARP1 drives dominance in these scenarios. Taken together, these findings highlight that the interconnected nature of cell death processes causes unexpected behaviors when these pathways are co-activated. Furthermore, we find that the rate of activation is a feature of antagonistic drug responses, with a previously unappreciated role in dictating functional interactions between cell death processes.
RESULTS

Optimization of a high-throughput assay for monitoring cell death kinetics
Drugs that induce different forms of cell death vary substantially in terms of their potency and their rates of activation 21 . Thus, to evaluate drug combinations comprised of apoptotic and non-apoptotic agents, we first optimized an assay that could be performed in a high-throughput scale while also retaining accurate analysis of death activation kinetics. Recently, methods have been developed for high-throughput measurement of cell death using SYTOX green in a fluorescence plate reader 17 . SYTOX green is a cell impermeable dye that fluoresces when bound to double stranded DNA. Furthermore, SYTOX fluorescence is specific to cell death, but largely agnostic to the mechanism by which cells die 22 . We made experimental and computational modifications to prior methods to enable an accurate inference of the numbers of live cells, dead cells, and total cells throughout the assay, rather than focusing only on the dead cells ( Fig. 1a ). Quantification of drug-induced death kinetics requires an accurate quantification of both live cells and dead cells over time, as inferences built from only one or the other of these measurements can be misleading 21 . To gain these insights, we measured of the initial lethal fraction prior to drug addition (e.g. percentage of dead cells relative to total cells), and at the assay end point (Fig. 1a ). To determine the lethal fraction at intermediate time points throughout the experiment, experimentally measured dead cell numbers (raw SYTOX values) at intermediate times were compared to computationally inferred total cell numbers at these time points ( Fig. 1a and Supplementary Fig. 1 ). This procedure enables the quantification of drug-induced changes in growth rate, death rate, and lethal fractions over time, including an analytical estimation of death onset time ( Fig. 1b and Supplementary Fig. 1 ). Furthermore, all of these measurements are computed from a single assay, and without the need for any specialized equipment. To evaluate the sensitivity of our assay we tested manual two-fold cell dilutions over a wide range of cell concentrations. We found that SYTOX green fluorescence of U2OS cells was linearly correlated with cell number from approximately 50 -20,000 cells per well, allowing accurate quantification of death rates even as low as 1% above background ( Fig.   1c ). To determine the accuracy of our assay -and in particular the accuracy of our death rate estimates -we compared our approach to STACK, an automated-microscopy-based approach that enables direct measurement of death kinetics by simultaneously measuring live and dead cells 21 . Overall, we found a strong correlation between our computationally inferred death rates and those observed using direct measurement ( Fig. 1e ).
Using our assay, we next characterized a panel of 54 drugs that are reported to kill cells using different forms of regulated cell death 16, [23] [24] [25] [26] [27] [28] [29] [30] . Drug responses were screened in U2OS cells, a cancer cell line with wild-type p53, which respond well to a diverse array of cell death inducing agents. Due to limited availability of markers to measure activation of some forms of death, we focused on a simplified classification scheme, categorizing drugs as non-lethal, apoptotic, or non-apoptotic. Non-lethal compounds were those whose effects were exclusively due to modulation of growth rate rather than through cell killing ( Supplementary Fig. 2-4 ). To distinguish between apoptotic and non-apoptotic drugs, we scored the degree to which the observed drug response was modulated in a BAX/BAK double knockout (DKO) genetic background relative to the wild-type (WT) parent U2OS cells ( Fig. 1f-g ). BAX and BAK are members of the BCL2 family of proteins and are pore forming proteins required for mitochondrial outer membrane permeabilization and subsequent apoptosis 31 . Drug classifications based on relative DKO vs. WT sensitivity were in agreement with categorization based on caspase-3 cleavage, a marker of activation of apoptosis ( Fig. 1h ). Overall, our classification strategy identified 9 non-lethal compounds, 30 apoptotic drugs, and 15 nonapoptotic drugs ( Fig. 1f -i and Supplementary Fig. 2-4 ).
Co-activation of apoptotic and non-apoptotic death is enriched for antagonism and single agent dominance
The different subtypes of regulated cell death are activated in a mutually exclusive manner, due to inhibitory interactions between the death pathways. These features have been found to be common among antagonistic drug-drug interactions 15 . Thus, we next aimed to test if co-activation of multiple death pathways would enrich for drug antagonism. Our strategy was to test all pairwise combinations of the 54 cell death-activating drugs that we evaluated as single agents. All single drugs and drug combinations were tested across 7 doses at a fixed dose ratio, and responses were measured every 4 hours over 48 hours ( Fig. 2a-b ). Biological replicates within the screen were highly correlated, suggesting a high degree of reproducibility within our assay (r2 > 0.98, Fig. 2c ). To score drug-drug interactions, we compared the observed responses to predicted responses given independent drug action ( Fig. 2b ). Overall we found 265 drug combinations that resulted in synergy, and 560 combinations that resulted in antagonism ( Fig. 2d ). These data were highly reproducible upon retesting with other assays (r2 > 0.8, Fig. 2e -f, and Supplementary Fig. 1d ).
Overall, in our "all-by-all" combinatorial drug screen nearly 60% of all combinations tested resulted in non-additive responses, with approximately 40% of all combinations resulting in antagonism ( Fig. 3a-b ). By comparison, other large-scale combination drug screens comprised of "random" drug combinations have identified antagonism at a frequency of 2-15% ( Fig. 3a-b) 32, 33 . Furthermore, we found a strong enrichment for antagonism specifically with drug combinations that involved two different classes of compounds (p = 0.03, Fishers exact).
Thus, as expected, our combination drug screen of cell death activating drugs is strongly enriched for antagonistic drug-drug interactions.
To more deeply analyze our data, we decided to focus on a large set of very strong antagonistic drug-drug interactions that we uncovered ( Fig. 3a) . While, nearly 40% of all combinations resulted in antagonism, many of these antagonistic responses were an extreme form in which the two drug combination phenocopied one of the two single agents ( Fig. 3c ). We call this response "single agent dominance" (SAD). The characteristic feature of SAD combinations is that an otherwise efficacious drug becomes fully suppressed by a second agent. For example, both SGI-1027, a DNA methyltransferase inhibitor that induces nonapoptotic death, and topotecan, a Topo I inhibitor that induces apoptosis, produced strong killing in U2OS cells when applied as single agents (Fig. 3c ). The combination of these two agents, however, resulted in precisely the same response as SGI-1027 alone ( Fig. 3c ). One relatively trivial explanation of this phenotype could be that very potent drugs tend to dominate simply because no additional cells remain to be killed (e.g. maximum potency was achieved by a single drug). To test this idea directly we tested all dose-dose combinations (e.g. rather than fixed dose ratios), to determine if low concentrations of a dominant drug (e.g. SGI-1027) would suppress high concentrations of a suppressed drug (e.g. topotecan). We found that even nonefficacious concentrations of SGI-1027 were sufficient to block death induced by high concentrations of topotecan ( Fig. 3d-f ). In fact, nearly all combinations of SGI-1027 and topotecan resulted in antagonism, regardless of the doses used ( Fig. 3f ). Overall, we identified 179 SAD combinations, which were 36% of all antagonistic drug-drug interactions.
The rate of drug-induced cell death is a key determinant of drug dominance
Considering the prominence of the SAD phenotype in our data, we next sought to gain a deeper understanding of the determinants of SAD antagonism by identifying features that were enriched within SAD combinations. In order to identify features of SAD combinations that might be helpful in predicting when/where these phenotypes will occur, we performed a multivariate analysis on the kinetic and pharmacological data generated by our SYTOX based cell death assay. To reduce the dimensionality of our data, we used principal component analysis (PCA).
Using PCA, 6 principal components were identified that captured over 85% of the variation in drug pharmaco-kinetics ( Fig. 4a ). Projection of the data onto PC1 and PC2 revealed a clear enrichment of SAD combinations for positivity on PC1, which captured 23.5% of the overall variation within our dataset ( Fig. 4b-c ). To determine which other PCs were capturing information related to SAD combinations, we scored the statistical enrichment for SAD combinations on each PC. SAD combinations were also enriched on PC2, which captured 19% of the drug response variation, and to a lesser extent on PC3 ( Fig. 4d ).
Considering the strong enrichment for SAD combinations on this subset of PCs, we next sought to determine what information about the drug response was being captured on PCs that are enriched for SAD combinations. To answer this question, we computed the Variable Importance in Projection, also called the VIP Score, which is a weighted sum of the relative magnitude of the regression coefficients for each input variable (i.e. a description of the importance of each variable in defining these principal components) 34 . Based on VIP scores, the onset time of cell death (D O ) stood out as being the most important variable associated with SAD combinations (Fig. 4e) . To determine what aspect of death onset time was related to the SAD phenotype, we examined the kinetics of cell death for the individual drugs that make up SAD combinations. We noticed a strong discrepancy in the rates of activation of dominant and suppressed drugs. For instance, in combinations of SGI-1027 and topotecan -a combination in which SGI-1027 is dominant -SGI-1027 kills cells earlier and at a faster rate than topotecan ( Fig. 4f ). To determine if differences in rates of activation were a common feature of SAD combinations, we explored the kinetic ratios for all 179 SAD combinations compared to 10,000 iterations of 179 random drug combinations in our data. This analysis confirmed that dominant drugs activate significantly faster and kill significantly earlier than their suppressed counterparts ( Fig. 4g ).
We next tested if the strong statistical correlation between onset time asymmetry and drug dominance was indicative of a causative relationship. To address this question our strategy was to temporally stagger the addition of dominant drugs, such that their activity occurred concomitantly with their suppressed counterparts. We tested this concept with the combination of MNNG and camptothecin, which results in robust domination by MNNG (Fig. 4h ). The addition of the suppressed drug later in time relative to the dominant drug did not affect overall drug response or the degree of MNNG dominance ( Fig. 4i) ; however, drug-drug antagonism and drug dominance were relieved when drug addition was staggered such that the suppressed agent is active at the same time as the dominant drug ( Fig. 4j -k). Thus, taken together these data suggest that faster acting drugs suppress slower acting drugs, leading to drug-drug antagonism and single agent dominance.
To determine the generalizability of these findings, we aimed to determine if differences in death onset time could be predictive of drug-drug antagonism and new SAD phenotypes in the absence of any other information about the drugs and their mechanisms of cell killing. We used publically available data on single drugs that have not yet been tested in combinations, but for which drug-induced death kinetics were available. Full kinetic data for drugs at varied doses were not available for any drugs; however, kinetic data were available for limited doses for a large panel of drugs from a recent study that explored the kinetics of cell death 21 . Our strategy to generate robust predictions from this sparse kinetic data was to incorporate the pharmacological and kinetic data for new drugs into our PCA model, along with publically available pharmacological (i.e. "dose response") data for drug responses in U2OS cells 35 .
These data were used to determine relative vector projections for new drugs in PC1 and PC2, which were associated with SAD combinations ( Supplementary Fig. 5-6 ).
Using this publicly available data, we identified 78 combinations among 15 drugs whose relative single agent profiles in PC1 and PC2 were similar to SAD combinations, suggesting drug dominance. We validated these predictions using our SYTOX based death assay ( Supplementary Fig. 6 ). In our validation screen, greater than 94% of the predicted SAD combinations resulted in drug antagonism, with 55% of these resulting in a SAD interaction ( Supplementary Fig. 6f -h). Thus, even in the absence of any information about the drugs and their mechanisms of action, an analysis of single drug pharmaco-kinetic properties was sufficient to identify new SAD combinations.
PARP1 dependent interactions between parthanatotic and apoptotic death mediate drug dominance
Our drug combination screen and subsequent computational analyses have revealed the overall prevalence and a general mechanism driving single agent dominance. Next we sought to gain a molecular understanding of these drug-drug interactions. Non-additivity is a feature often related to the underlying network structure of a drug's target proteins 12 . Given the diversity of the drugs tested and the limited understanding of pathways that regulate most forms of nonapoptotic death, we focused on studying a SAD combination that featured drugs with known regulatory pathway interactions. For example, hyper-activation of PARP1 causes parthanatos, a form of non-apoptotic cell death 16, 36 . Conversely, inhibition of PARP1 causes apoptosis due to "PARP trapping" and stabilization of DNA lesions 37 . Furthermore, PARP1 itself is cleaved and inactivated by caspase-3 20 . These data suggest a negative interaction between apoptotic and parthanatotic pathways, possibly due to the conflicting use of PARP1. To test this, we first evaluated the pathway activation dynamics of parthanatotic and apoptotic drugs at the level of PARP1 activation or inhibition. MNNG exposure leads to a transient hyper-activation of PARP1, resulting in increased protein PARylation (Fig. 5a ). Drug-induced PARP1 hyper-activation began minutes after drug exposure, and activity returned to baseline by roughly one hour following MNNG exposure. When treated with apoptotic drugs like camptothecin, PARP1 was not activated, but rather was cleaved and inactivated by caspase-3 ( Fig. 5b ). PARP1 cleavage did not occur until roughly 8-12 hours after camptothecin exposure ( Fig. 5c ). Thus, following exposure to MNNG or camptothecin, perturbations to PARP1 activity occur in distinct temporal windows, and in a mutually exclusive manner. When cells are exposed to both MNNG and camptothecin, PARP1 activation follows an MNNG-like dynamic pattern, consistent with the observed phenotypic dominance by MNNG over camptothecin ( Fig. 5a-c ).
Having determined that parthanatotic and apoptotic perturbations of PARP1 occur in a mutually exclusive manner, we next sought to determine if PARP1 is mechanistically involved in the MNNG-camptothecin SAD phenotype. To do so, we explored the fate of cells treated with MNNG and/or camptothecin in the presence or absence of a PARP1 inhibitor, rucaparib.
Although PARP1 inhibition by rucaparib can itself induce apoptosis, we used rucaparib at a sublethal dose, which was sufficient for blocking PARP1 activity ( Supplementary Fig. 7 ). Consistent with prior expectations, PARP1 inhibition largely blocked MNNG-mediated cell death, but enhanced camptothecin sensitivity ( Fig. 5d-e ). Interestingly, the MNNG dominance over camptothecin was lost when PARP1 was inhibited by rucaparib ( Fig. 5e-f ). Instead, in the presence of rucaparib, combinations of MNNG and camptothecin led to synergistically enhanced levels of cell death ( Fig. 5f ). Parthanatotic death, by definition, should not occur when PARP1 is inhibited 16 . Thus, we suspected that PARP1 inhibition changed not only the nature of the drug-drug interaction between MNNG and camptothecin, but also changed the mechanism of cell death induced by this combination. To test this, we began by evaluating markers of activation of apoptotic cell death. Indeed, using a flow cytometry based measurement of caspase-3 activation, we found that PARP1 inhibition by rucaparib switched the mechanism of killing induced by MNNG-camptothecin combinations from parthanatotic to apoptotic ( Fig. 5e,g) .
Thus, these data confirm that PARP1 mediates the interaction between parthanatotic and apoptotic death pathways, leading to antagonism and single agent dominance.
DISCUSSION
A common step in the development and evaluation of new compounds is to define a drug's mechanism of action, which is generally defined as a drug's direct binding target. Drug combinations could, in principle, then be designed based on known or perceived interactions between the targeted proteins. Here, we explore a complementary strategy of defining a drug's mechanism through its mechanism of cell killing, rather than its binding target. Our drug combination screen featuring drugs with varied killing mechanisms reveals a strong enrichment for non-additive drug-drug interactions, and in particular, enrichment for an extreme form of drug antagonism, which we call single agent dominance (SAD). Our statistical and computational analyses reveal that death onset rate is a major determinant of drug dominance. Furthermore, we successfully used drug-induced death rates to predict new SAD phenotypes in previously untested drug combinations. Future studies should determine the extent to which differences in drug activation rate predicts SAD combinations, or other non-additive drug-drug interactions, in other contexts.
The phenotypes uncovered in this study underscore the complexities of cell death regulation and the need for a greater mechanistic understanding of how different forms of cell death are controlled, both regarding the molecular mechanisms and kinetics of activation.
Regulated cell death provides an attractive target for therapeutic intervention, as cell killing is required for curative therapies 38 . As we demonstrated in the case of parthanatos and apoptosis, pathway interactions, or "crosstalk", likely account for the non-additive responses observed in these drug combinations. This is a particularly striking example, as PARP1 inhibitors are being explored in clinical settings, generally in combination with other cytotoxic therapies, and generally without regard to whether these companion therapies induce apoptotic or parthanatotic death 39, 40 . Thus in the case of PARP inhibitors, our data suggest that the effectiveness of these agents should also depend on the mechanisms by which companion compounds kill cells and, more importantly, the relative rates of activation of these drugs. More generally, considering the overall degree of antagonism and SAD within combinations of cell death targeting drugs, our data highlight the existence of widespread inhibitory crosstalk between death pathways. In most cases, however, we simply lack requisite knowledge on the death pathways activated by each drug and the molecular mechanisms by which most forms of cell death are regulated. In the long-term, predicting non-additive drug-drug interactions should be greatly improved by a deeper understanding of the network of interactions between different subtypes of regulated cell death.
A major benefit from our study is the identification of a "rule" that can be used to streamline the evaluation of drug combinations, namely that rates of drug-induced cell death can be used to predict drug-drug antagonisms. Recent studies have highlighted that drug synergy is not needed, and generally not observed, for clinically efficacious drug combinations 6, 7 . Nonetheless, drug-drug antagonism is likely to hinder treatment efficacy, particularly strong forms of antagonism, such as single agent dominance. Since drug-drug interactions are difficult to predict, current strategies rely mostly on screening drug combinations. This process is laborious due to the combinatorial expansion of possible drug combinations, which is further complicated by the fact that drug-drug interactions often depend on the doses used, the order in which the drugs are applied, the environment in which the drugs are applied, and the genotype(s) under evaluation 10, [41] [42] [43] [44] . Our study suggests that drugs may not need to be tested in combination in order to avoid SAD combinations, if the rates of drug induced death onset are known or can be measured ( Supplementary Fig. 8 ).
Thus, generating more detailed measurements of single drugs, while modestly more laborious in some experimental assays, would generate a much greater advantage of effectively removing the combinatorial complexity associated with compound screening ( Supplementary   Fig. 8 ). It has previously been recognized that the order of drug addition strongly alters the efficacy of drug combinations 5, 45 ; however, it had not been made clear from prior studies how one could predict optimal times in which to stagger the application of drugs. Our study suggests that staggering drug addition or drug release based on the onset of drug-induced cell killing may be an optimal strategy. Currently, standard approaches do not typically evaluate drug activation kinetics, instead focusing on the relationship between efficacy/potency and dose. These "dose-response" relationships have been the central focus of drug pharmacology data for over a century, and these relationships clearly reveal important insights about a given drug. The kinetic features of a drug are generally not predictable from single time point dose response data. Our study reveals that these "rate-response" relationships are observable in kinetic data, and that these relationships also produce unique insights into the nature of a given drug or drug combination.
Given the complementarity of pharmacological and kinetic data, evaluation of both of these types of data should become a new standard.
METHODS
Cell lines and reagents
U2OS cells were obtained from ATCC and maintained at low passage numbers (generally less than 20 passages from the original vial). Cells were grown in Dulbecco's modified eagles medium (DMEM) supplemented with 10% FBS, 2 mM glutamine, and penicillin/streptomycin. Drugs were purchased from either Selleck Chemicals, APEXBio Technology, or Sigma-Aldrich. 
U2OS mKate 2+ and BAX/BAK -/cell-line generation
NucLight red mKate2+ U2OS cells were generated by spin-fecting 6.33x106 TU/mL of NucLight Red virus (Essen Biosciences) with 8 ug/mL Polybrene and 1.5x10 6 cells at 2,000 rpm for 2 hours at 37 o C. After spinning, fresh DMEM was added and the cells were incubated overnight.
On the next day, cells were replated onto a 10 cm dish and grown to confluence. mKate+ cells were selected by FACS. BAX/BAK-/-U2OS cell line was generated using the pX330-puro plasmid with a hSpCas9 and BAX (GACAGGGGCCCTTTTGCTTC) or BAK (AGACCTGAAAAATGGCTTCG) sgRNA insert. U2OS cells were transiently transfected using FuGENE HD transfection reagent (Promega). BAX/BAK-/-cells were selected for using the BH3 mimetic Navitoclax (10 µM) for 5 days. Following Navitoclax treatment, cells were clonally selected.
SYTOX based measurement of cell death kinetics
SYTOX green was tested for linearity by plating cells at a 2-fold cell dilution from 20,000 cells to 1 cell in 5 µM SYTOX. After adhering, cells were lysed with 0.1% triton in PBS for 1.5 hours.
Fluorescence was measured on a Tecan M1000 plate reader at 503/524 excitation/emission.
Gain was set to capture linearity and for fluorescence to be at ~85% saturation of the detector. 
Cell-TiterGlo based measurement of relative viability
Cells were seeded at 2500 cells per well in 96-well plates and adhered overnight. On the day of drug addition 10X drug solutions were prepared as above in DMEM and added to the wells. 48 hours post-treatment, cells were lysed using according to the Cell-TiterGlo (Promega) manufacturer instructions and luminescence was read on a Tecan Spark I plate reader.
Relative viability was calculated as percent of DMSO control wells on the same plate.
Modeling drug induced cell death kinetics
The total number of dead cells at given time points can be determined by measuring SYTOX fluorescence. To determine the LF at a given time point, the starting number of plated cells (t = 0) and the post-triton cell number (t = 48) was fitted to an exponential equation for every treated well (assuming exponential growth) 46 . From the growth curve, the total number of cells could be determined for each condition at any time between 0 and 48 hours. Together with dead cell counts, a LF was determined for each drug and dose at all time points measured. Kinetic LFs could modeled using a Lag Exponential Death (LED) equation previously described previous 21 .
where LF 0 is the lethal fraction at time 0, LF p is the plateau, D O is the onset time of death, and D R is maximum rate of death. The model was constrained by 0< D 0 < 48, LF p < 1, and Dr < 2.
LF0 was left unconstrained due to basal levels of cell death. Drugs that did not produce max LF values 2x the LF 0 value were fit to a linear model.
Flow cytometry based analysis of apoptosis
Cells were seeded at 200,000 cells per well of 6 well dishes on the day prior to treatment and adhered overnight. For time course experiments, drugs were added in a manner such that all samples were collected at the same time. Post treatment, cells were collected and fixed with 4% formaldehyde for 15 minutes. After two washes with PBS, cells were exposed to 100% methanol at -20 o C for >2 hours. Cells were washed with PBS and incubated with the active 
Data availability
Source data for the drug combination screen are included in Supplementary Table 1 . All other data, MATLAB analysis scripts, will be made available upon request. 
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